At the time of writing, Kiniksa Pharmaceuticals International Plc [KNSA] stock is trading at $42.2, down -0.57%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KNSA shares have gain 11.29% over the last week, with a monthly amount drifted -3.03%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] stock has seen the most recent analyst activity on September 29, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $60. Previously, Citigroup started tracking the stock with Buy rating on March 13, 2025, and set its price target to $40. On September 13, 2024, Jefferies initiated with a Buy rating and assigned a price target of $40 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $34 on May 03, 2024. BofA Securities reiterated its recommendation of a Buy and raised its price target to $40 on June 29, 2020. BofA/Merrill started tracking with a Buy rating for this stock on April 01, 2020, and assigned it a price target of $25. In a note dated March 11, 2019, Barclays initiated an Overweight rating and provided a target price of $26 on this stock.
For the past year, the stock price of Kiniksa Pharmaceuticals International Plc fluctuated between $18.12 and $44.42. Currently, Wall Street analysts expect the stock to reach $53 within the next 12 months. Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] shares were valued at $42.2 at the most recent close of the market. An investor can expect a potential return of 25.59% based on the average KNSA price forecast.
Analyzing the KNSA fundamentals
According to Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA], the company’s sales were 597.97M for trailing twelve months, which represents an 61.17% jump. Gross Profit Margin for this corporation currently stands at 0.53% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.06%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.07 and Total Capital is 0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] has a current ratio of 3.85. Further, the Quick Ratio stands at 3.51, while the Cash Ratio is 1.41. Considering the valuation of this stock, the price to sales ratio is 5.35, the price to book ratio is 5.95 and price to earnings (TTM) ratio is 94.11.
Transactions by insiders
Recent insider trading involved Ragosa Mark, CHIEF FINANCIAL OFFICER, that happened on Jan 08 ’26 when 12000.0 shares were sold. Director, Quart Barry D completed a deal on Dec 15 ’25 to sell 20129.0 shares. Meanwhile, CHIEF OPERATING OFFICER Tessari Eben sold 12048.0 shares on Dec 15 ’25.
